Outcome according to specific therapeutic regimens
| . | AI . | HDAC . | Aza . | DAC . | P . |
|---|---|---|---|---|---|
| Total patients, n (%) | 178 (47%) | 83 (22%) | 47 (13%) | 67 (18%) | |
| Outcome | |||||
| ORR, n (%) | 87 (49%) | 44 (33%) | 12 (26%) | 21 (31%) | .001 |
| CR | 78 (44%) | 38 (46%) | 12 (26%) | 20 (30%) | .027 |
| CRp | 9 (5%) | 6 (7%) | 0 (0%) | 1 (1%) | NR |
| ED < 8 wk, n (%) | 37 (21%) | 17 (20%) | 7 (15%) | 6 (9%) | .149 |
| Median OS, mo | 5.5 | 8.1 | 5.5 | 8.8 | .164 |
| 1-y | 30% | 31% | 23% | 36% | |
| 2-y | 15% | 14% | 2% | 14% | |
| Median RFS, mo | 10.0 | 8.8 | 7.0 | 12.8 | .899 |
| 1-y | 41% | 36% | 30% | 45% | |
| 2-y | 20% | 28% | 30% | 45% | |
| . | AI . | HDAC . | Aza . | DAC . | P . |
|---|---|---|---|---|---|
| Total patients, n (%) | 178 (47%) | 83 (22%) | 47 (13%) | 67 (18%) | |
| Outcome | |||||
| ORR, n (%) | 87 (49%) | 44 (33%) | 12 (26%) | 21 (31%) | .001 |
| CR | 78 (44%) | 38 (46%) | 12 (26%) | 20 (30%) | .027 |
| CRp | 9 (5%) | 6 (7%) | 0 (0%) | 1 (1%) | NR |
| ED < 8 wk, n (%) | 37 (21%) | 17 (20%) | 7 (15%) | 6 (9%) | .149 |
| Median OS, mo | 5.5 | 8.1 | 5.5 | 8.8 | .164 |
| 1-y | 30% | 31% | 23% | 36% | |
| 2-y | 15% | 14% | 2% | 14% | |
| Median RFS, mo | 10.0 | 8.8 | 7.0 | 12.8 | .899 |
| 1-y | 41% | 36% | 30% | 45% | |
| 2-y | 20% | 28% | 30% | 45% | |
HDAC indicates high-dose ara-C; CRp, CR with incomplete platelet recovery; ED, early death; RFS, relapse-free survival; and NR, not reported.